Benchmark Maintains Buy on Cross Country Healthcare, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bill Sutherland maintains a Buy rating on Cross Country Healthcare (CCRN) but lowers the price target from $24 to $21.

February 22, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Benchmark analyst maintains a Buy rating on Cross Country Healthcare but lowers the price target from $24 to $21.
The adjustment in price target by Benchmark reflects a revised valuation perspective, yet the maintenance of a Buy rating indicates continued confidence in the company's fundamentals. This mixed signal could lead to short-term price stability as investors digest the implications of a lower price target against the backdrop of sustained analyst confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100